Jasmina Veta Darkovski, Medical Doctor at Universitätsklinikum Ulm shared a post on LinkedIn:
“The European Society of Gynecological Oncology Congress 2026 once again highlighted how dynamic and collaborative the field of gynecological oncology has become.
From multidisciplinary tumor board discussions with colleagues across Europe and beyond, to inspiring debates on practice-changing clinical trials in medical and surgical oncology, and highly educational surgical video sessions – the meeting provided an outstanding environment for scientific exchange and new collaborations.
I was honored to contribute by presenting two meta-analyses during the poster sessions.
Our pooled analysis on CDK4/6 inhibitors in low-grade serous ovarian carcinoma highlights endocrine-based CDK4/6 inhibition as a biologically rational and promising strategy in this rare and relatively chemoresistant tumor subtype.
In addition, our systematic review evaluating immune checkpoint inhibitors in endometrial and cervical cancer suggests that survival improvements with PD-(L)1 inhibitors can be achieved without clinically meaningful deterioration in health-related quality of life.
Both projects address a central question in modern oncology: How can we improve survival while preserving our patients’ quality of life?
Because if we improve survival without worsening quality of life, we are truly advancing patient-centered oncology.
Thank you to the European Society of Gynecological Oncology team for creating such an inspiring scientific environment. Looking forward to continuing these discussions in London next year.
Special thanks to the Meta-Analysis Academy , whose mentorship and methodological training made these projects possible.”
Other articles about Gynecologic Oncology on OncoDaily.
